A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
Running, not enrolling · Phase 3 · Has a placebo group
Conditions studied: Obesity, Overweight
In brief
The main purpose of this study is to see how orforglipron, compared with placebo, helps reduce body weight in participants with obesity or with overweight and at least one other related health condition (excluding type 2 diabetes). This trial is part of the master protocol study J2A-MC-GZPO (NCT06993792). Participation in the study will last about 18 months.
Key facts
- Study ID
- NCT06972459
- Run by
- Eli Lilly and Company
- People needed
- 800
- Starts
- 2025-05-15
- Expected to finish
- 2027-08-01
- Last updated by the study team
- 2026-07-29
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Have body mass index (BMI) ≥30 kilograms per square meter (kg/m2) or BMI ≥25.0 kg/m2 and at least 1 of the following weight-related comorbidities at screening:
- hypertension
- dyslipidemia
- obstructive sleep apnea, or
- cardiovascular disease
- Have a history of at least one unsuccessful dietary effort to lose body weight
You may not qualify if…
- Have type 1 diabetes, type 2 diabetes, or any other types of diabetes
- Have an unstable body weight within 90 days prior to screening
- Have New York Heart Association functional classification IV congestive heart failure or an acute cardiovascular condition within 90 days prior to screening
- Have acute or chronic hepatitis or pancreatitis
- Are taking other medications or alternative remedies to manage weight loss
Where it is running
- Novak Clinical Research - Tucson - North La Cholla Boulevard — Tucson, Arizona, United States
- Norcal Endocrinology & Internal Medicine — San Ramon, California, United States
- Southern California Clinical Research — Santa Ana, California, United States
- Care Access - Thousand Oaks — Thousand Oaks, California, United States
- Accel Research Sites - DeLand Clinical Research Unit — DeLand, Florida, United States
- Innovation Medical Research Center - Fort Lauderdale — Fort Lauderdale, Florida, United States
- Indago Research & Health Center, Inc — Hialeah, Florida, United States
- Encore Medical Research — Hollywood, Florida, United States
- West Orange Endocrinology P.A. — Ocoee, Florida, United States
- Care Access - Tampa — Tampa, Florida, United States
- Conquest Research — Winter Park, Florida, United States
- Accel Research Sites - NeuroStudies Clinical Research Unit — Decatur, Georgia, United States
- Care Access - Decatur — Decatur, Georgia, United States
- Javara - Privia Medical Group Georgia - Savannah — Savannah, Georgia, United States
- North Georgia Clinical Research — Woodstock, Georgia, United States
- Solaris Clinical Research — Meridian, Idaho, United States
- Care Access - New Iberia — New Iberia, Louisiana, United States
- Endocrine and Metabolic Consultants — Rockville, Maryland, United States
- Javara - Privia Medical Group - Silver Spring — Silver Spring, Maryland, United States
- Great Lakes Research Group, Inc. — Bay City, Michigan, United States
- Boeson Research MSO — Missoula, Montana, United States
- Javara - Nevada Health Centers - Carson City — Carson City, Nevada, United States
- The Machuca Foundation — Las Vegas, Nevada, United States
- University of North Carolina Medical Center — Chapel Hill, North Carolina, United States
- Clinical Research Institute of Arizona (CRI) - Sun City West — Sun City West, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.